- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - Astellas to lead commercialization of VIR-5500...
Phase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in both early and late-line metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March: ...
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious...
Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious...
March S&P 500 E-Mini futures (ESH26) are down -0.04%, and March Nasdaq 100 E-Mini futures (NQH26) are up +0.21% this morning as sentiment remains cautious following yesterday’s selloff on Wall Street...
– Announces global strategic collaboration with Astellas to advance PSMA-targeted PRO-XTEN ® dual-masked T-cell engager (TCE) VIR-5500 for the treatment of prostate cancer ...
– Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date ...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate update and discuss its financial results...
– Positive, updated Phase 2 SOLSTICE data showed combination of tobevibart and elebsiran is well tolerated and achieved undetectable HDV RNA in 88% of chronic hepatitis delta...